pregabalina stada 200 mg capsulas duras efg
laboratorio stada s.l. - pregabalina - cÁpsula dura - 200 mg - pregabalina 200 mg - pregabalina
pregabalina stada 50 mg capsulas duras efg
laboratorio stada s.l. - pregabalina - cÁpsula dura - 50 mg - pregabalina 50 mg - pregabalina
pregabalina stada 25 mg capsulas duras efg
laboratorio stada s.l. - pregabalina - cÁpsula dura - 25 mg - pregabalina 25 mg - pregabalina
pregabalina stada 75 mg capsulas duras efg
laboratorio stada s.l. - pregabalina - cÁpsula dura - 75 mg - pregabalina 75 mg - pregabalina
pregabalina stada 150 mg capsulas duras efg
laboratorio stada s.l. - pregabalina - cÁpsula dura - 150 mg - pregabalina 150 mg - pregabalina
pregabalina stada 300 mg capsulas duras efg
laboratorio stada s.l. - pregabalina - cÁpsula dura - 300 mg - pregabalina 300 mg - pregabalina
oyavas
stada arzneimittel ag - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - agentes antineoplásicos - oyavas in combination with fluoropyrimidine based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. oyavas in combination with paclitaxel is indicated for first line treatment of adult patients with metastatic breast cancer. para obtener más información sobre el estado del receptor 2 del factor de crecimiento epidérmico humano (her2), consulte la sección 5. oyavas in combination with capecitabine is indicated for first line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with oyavas in combination with capecitabine. para más información sobre el estado de her2, consulte la sección 5. oyavas, in addition to platinum based chemotherapy, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non small cell lung cancer other than predominantly squamous cell histology. oyavas, in combination with erlotinib, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non squamous non small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations (see section 5. oyavas in combination with interferon alfa 2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. oyavas, in combination with carboplatin and paclitaxel is indicated for the front line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5. oyavas, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor–targeted agents. oyavas, in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents (see section 5. oyavas, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5.
abiraterona stada 500 mg comprimidos recubiertos con pelicula efg
laboratorio stada s.l. - abiraterona acetato - comprimido recubierto con pelÍcula - 500 mg - abiraterona acetato 500 mg - abiraterona
acido alendronico/colecalciferol semanal stada 70 mg/2.800 ui comprimidos efg
laboratorio stada s.l. - alendronico acido; colecalciferol - comprimido - 70 mg/2.800 ui - alendronico acido 70 mg; colecalciferol 2800 ui - Ácido alendrónico y colecalciferol
acido alendronico/colecalciferol semanal stada 70 mg/5.600 ui comprimidos efg
laboratorio stada s.l. - alendronico acido; colecalciferol - comprimido - 70 mg/5.600 ui - alendronico acido 70 mg; colecalciferol 5600 ui - Ácido alendrónico y colecalciferol